Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A susceptibility or predisposition to cutaneous melanoma (disease) that is caused by an inherited modification of the individual's genome.
No HPO annotations are available for this condition.
Cardiofaciocutaneous (CFC) syndrome is a multiple congenital anomaly disorder in which individuals may have dysmorphic craniofacial features, cardiac issues, skin and hair abnormalities, hypotonia, eye abnormalities, gastrointestinal dysfunction, seizures, and varying degrees of neurocognitive delay . While many features have been seen in association with this condition, individuals with CFC syndrome display phenotypic variability and therefore not all have every finding. Polyhydramnios is present in the vast majority of fetal cases diagnosed in utero. Maternal hyperemesis gravidarum, gestational diabetes, gestational hypertension, and preeclampsia may occur, and subjective decrease in fetal movement may be observed prenatally. Second- and third-trimester ultrasound abnormalities may include polyhydramnios, macrocephaly, macrosomia, and renal and cardiac abnormalities. Operative delivery is not uncommon. Neonatal outcomes of CFC individuals may include irregular heartbeat, intubation, need for feeding tube, edema, chylothorax, and hyperbilirubinemia, which may be confounded by the increased rate of prematurity . Table 2. Cardiofaciocutaneous Syndrome: Frequency of Select Features
Cardiofaciocutaneous (CFC) syndrome is one the RASopathies: a group of syndromes having overlapping clinical features resulting from a common pathogenetic mechanism . No consensus clinical diagnostic criteria have been established. The diagnosis of CFC syndrome is suspected by clinical findings and confirmed by molecular genetic testing.
Cardiofaciocutaneous (CFC) syndrome should be suspected in individuals with the following clinical features:
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
No approved treatments are currently available for susceptibility to familial cutaneous melanoma. The disease remains an area of unmet medical need.
Clinical practice guidelines for cardiofaciocutaneous (CFC) syndrome have been published (full text). Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with CFC syndrome, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Cardiofaciocutaneous (CFC) Syndrome
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations in are recommended. Lifelong periodic follow up is warranted. Table 6. Recommended Surveillance for Individuals with Cardiofaciocutaneous Syndrome
51 clinical trials registered, 24 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 3 PHASE3, 10 PHASE2, 20 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06319196](https://clinicaltrials.gov/study/NCT06319196) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:04 PM UTC
Feature | Frequency | Comment |
|---|---|---|
Nearly all | Common | Less frequent |
Hypotonia motor developmental delay | Seizures | Behavioral issues |
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
Costello syndrome. By definition, individuals identified as having a heterozygous HRAS pathogenic variant have the diagnosis of Costello syndrome. Costello syndrome is characterized by the following:
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Complete physical exam incl measurement of growth parameters | To assess for poor growth |
Neurologic | Neurologic eval1 | To incl brain MRI in persons w/rapid in head growth, regression of developmental skills, seizures, changes in neurologic findings, or concerns about optic nerve hypoplasia on ophthalmologic eval; Consider EEG if seizures are a concern. |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Psychiatric/ |
Behavioral | Neuropsychiatric eval | For persons age 12 mos: screening for behavior concerns incl sleep disturbances, ADHD, anxiety, /or findings suggestive of ASD Gastrointestinal/ |
Feeding | Gastroenterology/ nutrition/ feeding team eval | To incl eval of aspiration risk nutritional status; Consider swallowing study /or studies for GERD.; Consider eval for gastrostomy tube placement in persons w/dysphagia /or aspiration risk.; Be mindful of possible malrotation.; Assessment for signs/symptoms of constipation |
Eyes | Ophthalmologic eval | To assess for ptosis, amblyopia, refractive error, strabismus, optic nerve abnormalities, cataracts, delayed visual maturation, cortical visual impairment, or more complex findings that may require subspecialty referral |
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Contractures, hip dysplasia, kyphoscoliosis; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Hearing | Audiologic eval | Assess for hearing loss. |
Cardiovascular | Cardiac eval incl measurement of blood pressure, echocardiogram, electrocardiogram | With special assessment for pulmonary stenosis, hypertrophic cardiomyopathy, /or septal defects; If there are concerns about arrhythmia, then consider 24-hour Holter eval. |
Genitourinary | Abdominal ultrasound | To evaluate for renal (rarely) splenic anomalies Consider pelvic ultrasound. |
Skin | Dermatologic eval2 | Skin issues typically evolve over time.; If there is significant lymphedema or large hemangiomas, consider referral to vascular anomalies specialist or clinic. |
Endocrine | Consider obtaining TSH, free T4, IGF-1, IGFBP-3. | Consider referral to endocrinologist. Consider celiac disease screening in those w/growth failure. Physical exam for evidence of precocious puberty in children for initiation progression through puberty in adolescents Obtain DXA scan in younger older adults |
Hematologic/Lymphatic | CBC w/platelet count, platelet function studies, von Willebrand screening | In persons w/history of bruising or bleeding problems, consider referral to hematologist if there are abnormalities on these screening blood tests.; Eval for bleeding issues should be done prior to any invasive or surgical procedure. |
Respiratory/Sleep | Clinical assessment for signs symptoms of tracheomalacia in infants young children | Laryngotracheal abnormalities such as laryngotracheomalacia laryngeal clefts have been reported. Consider sleep study. |
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
Individuals with CFC syndrome report heat intolerance; therefore, overexposure to heat and strenuous activity should be avoided. Hydrate as needed. In individuals with evidence of peripheral neuropathy, drugs with a neurotoxic effect should be avoided, per standard supportive treatment according to the individual's neurologist or rehabilitation medicine specialist.
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
51 trials found
System/Concern
Evaluation |
|---|
Frequency |
|---|
Development | Monitor developmental progress educational needs. | At each visit |
Eyes | Monitor for ocular issues (such as myopia, hyperopia, cataracts) by ophthalmologist | Every 6-12 mos as directed by ophthalmologist |
Musculoskeletal | Assess for scoliosis3,4 | At each visit until skeletal maturity |
Hearing | Hearing eval | Every 2-3 yrs, or more frequently if hearing loss has been identified |
Cardiovascular5 | Blood pressure measurement | At each clinic visit Persons up to age 20 yrs |
Skin | Dermatologic eval for skin issues, progression of nevi formation, monitoring of lymphedema | Annually or as directed by dermatologist Endocrine |
Source: GeneReviews — "Cardiofaciocutaneous Syndrome"
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma |
PHASE2 |
University Health Network, Toronto |
RECRUITING |
[NCT06887348](https://clinicaltrials.gov/study/NCT06887348) | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 | — | Replimune, Inc. | RECRUITING |
[NCT06624644](https://clinicaltrials.gov/study/NCT06624644) | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | PHASE2 | Linnaeus Therapeutics, Inc. | RECRUITING |
[NCT06753136](https://clinicaltrials.gov/study/NCT06753136) | Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype | NA | Istituto Oncologico Veneto IRCCS | RECRUITING |
[NCT06999980](https://clinicaltrials.gov/study/NCT06999980) | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | PHASE2 | Melanoma Institute Australia | RECRUITING |
25 publications have been identified in PubMed for susceptibility to familial cutaneous melanoma. Research spans Epidemiology / Natural History (28%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 7 | 28% |
Research summaries | 5 | 20% |
Patient case studies | 5 | 20% |
Laboratory research | 5 | 20% |
Clinical study results | 2 | 8% |
New treatment approaches | 1 | 4% |
Leite SJ (2026). [PMID: 42180414](https://pubmed.ncbi.nlm.nih.gov/42180414/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Landi MT (2026). [PMID: 42183343](https://pubmed.ncbi.nlm.nih.gov/42183343/). *Res Sq*. [Basic Science / Preclinical]
Pálla S (2026). [PMID: 41165034](https://pubmed.ncbi.nlm.nih.gov/41165034/). *International journal of dermatology*. [Review / Meta-Analysis]
Siddiqui FS (2026). [PMID: 40811605](https://pubmed.ncbi.nlm.nih.gov/40811605/). *Unknown Journal*. [Review / Meta-Analysis]
Naeser Y (2026). [PMID: 41386727](https://pubmed.ncbi.nlm.nih.gov/41386727/). *International journal of cancer*. [Epidemiology / Natural History]
Goldstein AM (2026). [PMID: 42201696](https://pubmed.ncbi.nlm.nih.gov/42201696/). *JAMA Dermatol*. [Epidemiology / Natural History]
Ragnarsson KA (2026). [PMID: 41712014](https://pubmed.ncbi.nlm.nih.gov/41712014/). *Familial cancer*. [Case Report / Case Series]
Johansson PA (2026). [PMID: 41673532](https://pubmed.ncbi.nlm.nih.gov/41673532/). *Pigment cell & melanoma research*. [Basic Science / Preclinical]
Delcoigne B (2025). [PMID: 39999038](https://pubmed.ncbi.nlm.nih.gov/39999038/). *The British journal of dermatology*. [Epidemiology / Natural History]
Nicolaisen TJ (2025). [PMID: 40571914](https://pubmed.ncbi.nlm.nih.gov/40571914/). *BMC veterinary research*. [Case Report / Case Series]